We appreciate the interest of Drs. Shen, Zhang, Lu, Schwartz, and Yang in our article, and we appreciate the opportunity to respond to their comments.
Reply:
We appreciate the interest of Drs. Shen, Zhang, Lu, Schwartz, and Yang in our article, and we appreciate the opportunity to respond to their comments.
We agree that propensity score-matching analysis (PSA) should be used in observational studies. In fact, we have assessed the impact of perioperative blood transfusion on long-term survival using PSA despite the small patient numbers in our study (n=66). The PSA between the patients who received perioperative blood transfusion and those who did not showed that perioperative blood transfusion was a significantly prognostic factor for poor survival (hazard ratio (HR)= 3.125 (95 % confidence interval (CI), 1.007-9.709), P= 0.049), but not for recurrence (HR=2.538 (95 % CI, 0.938-6.849), P=0.067). En bloc resection of the caudate lobe and extrahepatic bile duct along with major liver resection can lead to a large amount of blood loss and a need for blood transfusion, but like most centers, our experience remains limited. If the number of such aggressive surgeries for hilar cholangiocarcinoma (HCCA) increases in the future at our institute, PSA may demonstrate perioperative blood transfusion to be a significant predictive factor for not only poor survival but also for recurrence.
Dr. Shen et al. have pointed out that we did not select some variables such as ASA score, preoperative hemoglobin level, tumor location, and concomitant vascular resection. We did not regard ASA score as an important variable because all of the patients in our study had an ASA score of 1 or 2. We agree that the preoperative hemoglobin level might affect perioperative blood transfusion requirements, but we did not collect this data. Portal vein resection (PVR) and hepatic artery resection were performed in 11 and 1 cases, respectively. We analyzed the relationship between PVR and survival, but PVR was not a significant factor for recurrence (P=0.324) and survival (P=0.274) in univariate analysis.
Previously, Peduzzi et al. 1 recommended B10 events per variable^in multivariate analysis. In our study, all variables that were significant in univariate analysis were included in multivariate analysis to identify independent predictors for survival. Consequently, we selected 9 variables and 12 variables for recurrence and poor survival, respectively, in multivariate analysis. However, even if we selected any 6 or 7 variables including blood transfusion, blood transfusion was one of the strongest predictors for both recurrence and poor survival in multivariate analysis.
We strongly believe that the immunosuppressive effect of blood transfusion may play a major role in recurrence of malignant tumors, as we described in the discussion on our article.
2 Many articles about the negative effects of blood transfusion have been reported since 1982, including increased recurrence of malignant tumors. Recently, some studies have suggested that perioperative blood transfusion has no negative impact on long-term oncologic outcomes using PSA as Dr. Shen et al. emphasize. [3] [4] [5] On the other hand, other studies have focused on the negative impact of blood transfusion on long-term outcome for several malignant tumors in meta-analysis [6] [7] [8] and PSA. 9 We understand that our study has the limitations of a retrospective survey and a small sample size. However, we have demonstrated that the negative impact of blood transfusion cannot be ignored at this time. While we hope that our results will be confirmed by a prospective randomized control trial or PSA in the future, but we suspect that ethical considerations may mean that such a randomized trial cannot take place.
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